Your search returned 45 studies. (Get alerts for new studies):
- Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Conditions: Solid Tumors - Lymphomas
1 Location available
- Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Conditions: Leukemia - Unspecified Childhood Solid Tumor, Protocol Specific
21 Locations available
- Ipilimumab in Young Patients With Advanced or Refractory Solid Tumors
Conditions: Adult Malignant Fibrous Histiocytoma of Bone - Childhood Malignant Fibrous Histiocytoma of Bone - Kidney Cancer - Lymphoma - Melanoma (Skin) - Neuroblastoma - Sarcoma - Unspecified Adult Solid Tumor, Protocol Specific - Unspecified Childhood Solid Tumor,
3 Locations available
- Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
Conditions: Leukemia, Myeloid, Acute - Leukemia, Lymphocytic, Acute, T-Cell - Juvenile Myelomonocytic Leukemia Lymphoblastic - T-cell Lymphoblastic Lymphoma - Myelodysplastic Syndrome
1 Location available
- Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
Conditions: Refractory Solid Tumors - Leukemia
1 Location available
- IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
Conditions: Breast Cancer - Lung Cancer - Melanoma - Pancreatic Cancer - Solid Tumors
1 Location available
- A Trial of RAD001 and Avastin in Children With Recurrent Solid Tumors
Conditions: Recurrent or Refractory Solid Tumors - CNS Malignancies
1 Location available
- A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
Conditions: Solid Tumor
1 Location available
- Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Conditions: Adrenocortical Carcinoma - Kidney Cancer - Liver Cancer - Neuroblastoma - Retinoblastoma - Sarcoma
97 Locations available
- A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma, Solid Cancers
1 Location available
- A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Non-Hodgkin's Lymphoma, Solid Cancers
2 Locations available
- Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions: Brain and Central Nervous System Tumors - Lymphoma - Neuroblastoma - Unspecified Childhood Solid Tumor, Protocol Specific
25 Locations available
- A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Re
Conditions: Refractory Solid Tumors in Children
1 Location available
- Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Conditions: Cancer
3 Locations available
- ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Per
Conditions: Ovarian Cancer - Primary Peritoneal Cavity Cancer - Unspecified Adult Solid Tumor, Protocol Specific
3 Locations available
- First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor EMD 1214063 in Subjects With Advanced Solid Tumors
Conditions: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
1 Location available
- Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Conditions: Refractory Head and Neck Cancer, Squamous Cell Carcinoma of the Skin, Carcinoma of the Breast, and Malignant Melanoma
4 Locations available
- PD 0332991 in Treating Patients With Refractory Solid Tumors
Conditions: Adult Solid Tumor - Adenocarcinoma of the Colon - Adenocarcinoma of the Rectum - Adult Central Nervous System Germ Cell Tumor - Adult Teratoma - Benign Teratoma - Estrogen Receptor-negative Breast Cancer - Estrogen Receptor-positive Breast Cancer - Famili
1 Location available
- A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumors - Recurrent or Refractory Medulloblastoma - Locally Advanced or Metastatic Basal Cell Carcinoma
2 Locations available
- Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Young Patients With Relapsed or Refractory Solid Tumors
Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
21 Locations available
- MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Brain and Central Nervous System Tumors - Childhood Germ Cell Tumor - Kidney Cancer - Leukemia - Liver Cancer - Neuroblastoma - Sarcoma
86 Locations available
- First in Man Study of SAR566658 Administered Every 3 Weeks in Patients With DS6-positive and Refractory Solid Tumors
Conditions: Neoplasm Malignant
2 Locations available
- RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors - Breast Cancer - Colorectal Cancer - Lymphoma - Lymphoproliferative Disorder - Small Intestine Cancer - Unspecified Adult Solid Tumor, Protocol Specific
1 Location available
- Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
Conditions: Leukemia - Unspecified Adult Solid Tumor, Protocol Specific
2 Locations available
- Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
Conditions: Neuroblastoma - Rhabdomyosarcoma - Lymphoma - Wilm's Tumor - Ewing's Sarcoma
2 Locations available
- MEK Inhibitor AZD6244 and Cetuximab Treating Patients With Advanced or Refractory Solid Tumors That Cannot Be Removed By Surgery
Conditions: Colorectal Cancer - Unspecified Adult Solid Tumor, Protocol Specific
1 Location available
- A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma
Conditions: Solid Cancers
2 Locations available
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Brain and Central Nervous System Tumors - Leukemia - Lymphoma - Lymphoproliferative Disorder - Small Intestine Cancer - Unspecified Childhood Solid Tumor, Protocol Specific
22 Locations available
- Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
20 Locations available
- AT13387 in Treating Patients With Refractory Solid Tumors
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
1 Location available
- AT13387 in Adults With Refractory Solid Tumors
Conditions: Solid Tumors - Breast Cancer
1 Location available
- EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors
Conditions: Neoplasms
1 Location available
- Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
Conditions: Solid Tumors - Brain Tumors - Brain Metastases
1 Location available
- Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
Conditions: Brain and Central Nervous System Tumors - Lymphoma - Lymphoproliferative Disorder - Small Intestine Cancer - Unspecified Childhood Solid Tumor, Protocol Specific
21 Locations available
- Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Conditions: Solid Tumors - Relapsed/Refractory Sarcomas
2 Locations available
- Bevacizumab and Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin in Treating Patients With Refractory Solid Tumors
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
1 Location available
- Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Conditions: Glioblastoma Multiforme
1 Location available
- Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors
Conditions: Solid Tumors
2 Locations available
- Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
Conditions: Melanoma - Metastatic Melanoma - Solid Tumor
2 Locations available
- Sorafenib (BAY 43-9006) to Treat Children With Solid Tumors or Leukemias
Conditions: Refractory Solid Tumors - Refractory Leukemias
1 Location available
- Oral Azacitidine as a Single Agent and in Combination With Carboplatin or Abraxane® in Subjects With Relapsed or Refractory Solid Tumors
Conditions: Relapsed or Refractory Solid Tumors
4 Locations available
- Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Conditions: Brain and Central Nervous System Tumors - Unspecified Childhood Solid Tumor, Protocol Specific
11 Locations available
- Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
2 Locations available
- A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Conditions: Lymphoma, Solid Tumour
1 Location available
- Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
Conditions: Solid Tumors - Lymphoma
2 Locations available
|